Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 13/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5032059 | 0.87 | IMPDH2 (0.66) | IMPDH2LMNAPKMNPC1RAB9A | |
| SCHEMBL14364371 | 0.84 | LMNA (0.47) | CYP11B1CYP11B2IMPDH2LMNAPKM | |
| SCHEMBL8227757 | 0.79 | MAP4K4 (0.54) | CYP11B1CYP11B2IMPDH2LMNAPKM | |
| SCHEMBL5032038 | 0.76 | IMPDH2 (0.55) | IMPDH2LMNAPKMNPC1RAB9A | |
| SCHEMBL4769462 | 0.75 | IL2 (0.61) | IMPDH2LMNAPKMNPC1RAB9A | |
| SCHEMBL5130878 | 0.74 | IMPDH2 (0.39) | CYP11B1CYP11B2IMPDH2LMNAPKM | |
| SCHEMBL5029427 | 0.74 | IMPDH2 (0.59) | IMPDH2LMNAPKMNPC1RAB9A | |
| SCHEMBL5130882 | 0.74 | IMPDH2 (0.39) | CYP11B1CYP11B2IMPDH2LMNAPKM | |
| SCHEMBL5027378 | 0.74 | IL2 (0.44) | IMPDH2ALDH1A1 | |
| SCHEMBL5027352 | 0.73 | IMPDH2 (0.55) | IMPDH2LMNAPKMNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140242120-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8741960-B2 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-1983971-A2 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070249050-A1 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007087441-A2 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249050-A1 | Substituted aromatic compounds for inflammation and immune-related uses | CCR1, NLRP1, NLRP3 | CYP11B1 487/4885CYP11B2 881/4885IMPDH2 3907/4885 |
| US-20140242120-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, NLRP1, NLRP3 | CYP11B1 487/4885CYP11B2 881/4885IMPDH2 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.